The Benefit trial: Testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease

Memorias do Instituto Oswaldo Cruz

Volumn 104, Issue SUPPL. 1, 2009, Pages 319-324

  Antonio Marin Neto, J ^a   Rassi Jr , Anis ^b   Avezum Jr , Alvaro ^c   Mattos, Antonio C ^c   Rassi, Anis ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Anis Rassi Hospital   (Brazil)

^c INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

Antitrypanosomal therapy; Benznidazole; Chagas cardiomyopathy; Chagas disease; Clinical trials

Indexed keywords

TRYPANOSOMA CRUZI;

EID: 68949220484     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/s0074-02762009000900042     Document Type: Article

References (41)

1. Amorim DS, Marin-Neto JA 1995. Functional alterations of the auto-nomic nervous system in Chagas' heart disease. São Paulo Med J 113: 772-784.
2. Andrade AL, Zicker F, de Oliveira RM, Almeida Silva S, Luquetti A, Travassos LR, Almeida IC, De Andrade SS, de Andrade JG, Martelli CM 1996. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348: 1407-1413.
3. Andrade SG, Stocker-Guerret S, Pimentel AS, Grimaud JA 1991. Reversibility of cardiac fibrosis in mice chronically infected with Trypanosoma cruzi, under specific chemotherapy. Mem Inst Oswaldo Cruz 86: 187-200.
4. Bellotti G, Bocchi E, de Moraes AV, Higuchi ML, Barbero-Marcial M, Sosa E, Esteves-Filho A, Kalil R, Weiss R, Jatene A, Pileggi F 1996. In vivo detection of T. cruzi antigens in hearts of patients with chronic Chagas' heart disease. Am Heart J 131: 301-307.
5. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, Maguire JH, Acquatella H, Morillo C, Kirchhoff LV, Gilman RH, Reyes PA, Salvatella R, Moore AC 2007. Evaluation and treatment of Chagas disease in the United States. A systematic review. JAMA 298: 2171-2181.
6. Britto C, Cardoso MA, Vanni CM, Hasslocher-Moreno A, Xavier SS, Oelemann W, Santoro A, Pirmez C, Morel CM, Wincker P 1995. Polymerase chain reaction detection of Trypanosoma cruzi in human blood samples as a tool for diagnosis and treatment evaluation. Parasitology 110: 241-247.
7. Britto C, Silveira C, Cardoso MA, Marques P, Luquetti A, Macedo V, Fernandes O 2001. Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction. Mem Inst Oswaldo Cruz 96: 823-826.
8. Catalioti F, Acquatella H 1999. Comparación de mortalidad duran-te seguimiento por 5 años en sujetos con enfermedad de Chagas crónica con y sin tratamiento de benznidazol. Primer simposio virtual en enfermedad de Chagas. Available from: http://pcvc. sminter.com.ar/cvirtual/tlibres/tnn2574/tnn2574.htm.
9. Chagas C 1909. Über eine neue trypanosomiasis des Menschen. Archiv Schiffs Tropen Hyg 13: 5-7.
10. Coura JR 2007. Chagas disease: what is known and what is needed. A background article. Mem Inst Oswaldo Cruz 102 (Suppl. I): 113-122.
11. Coura JR, de Abreu LL, Willcox HP, Petana W 1997. Comparative controlled study on the use of benznidazole, nifurtimox and placebo in the chronic form of Chagas disease, in a field area with interrupted transmission. I. Preliminary evaluation. Rev Soc Bras Med Trop 30: 139-144.
12. Cunha-Neto E, Bilate AM, Hyland KV, Fonseca SG, Kalil J, Engman DM 2006. Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 39: 41-54.
13. Dias JC, Prata A, Correia D 2008. Problems and perspectives for Chagas disease control: in search of a realistic analysis. Rev Soc Bras Med Trop 41: 193-196.
14. Dias JCP 1989. The indeterminate form of human chronic Chagas' disease: a clinical epidemiological review. Rev Soc Bras Med Trop 22: 147-156.
15. Fabbro De Suasnábar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, Amicone N 2000. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 42: 99-109.
16. Fragata Filho AA, Boianain E, Silva MAD, Correia EB, Borges Filho R, Martins C, Salene V, Batlouni M, Souza E 1995. Validade do tratamento etiológico da fase crônica da doença de Chagas com benznidazol. Arq Bras Cardiol 65 (Suppl. I): 71.
17. Gallerano RH, Sosa RR 2001. Resultados de estúdio a largo plazo com drogas antiparasitárias em infectados chagásicos crônicos. Rev Fed Arg Cardiol 30: 289-296.
18. Galvao LM, Chiari E, Macedo AM, Luquetti AO, Silva SA, Andrade AL 2003. PCR assay for monitoring Trypanosoma cruzi parasitemia in childhood after specific chemotherapy. J Clin Microbiol 41: 5066-5070.
19. Garcia S, Ramos CO, Senra JFV, Vilas-Boas F, Rodrigues MM, Cam-pos-de-Carvalho AC, Ribeiro-Dos-Santos R, Soares MB 2005. Treatment with benznidazole during the chronic phase of experimental CD decreases cardiac alterations. Antimicrob Agents Chemother 49: 1521-1528.
20. Ianni BM, Arteaga E, Mady C, Barretto ACP, Pileggi F 1993. Uso de benznidazol em chagásicos na forma indeterminada: resultados a longo prazo. Arq Bras Cardiol 61 (Suppl. II): 130.
21. Kierszenbaum F 2007. Mechanisms of pathogenesis in Chagas disease. Acta Parasitol 52: 1-12.
22. Köberle F 1968. Chagas' heart disease and Chagas' syndromes: the pathology of American trypanosomiasis. Adv Parasitol 6: 63-116.
23. Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simões-Barbosa A, Tinoco DL, Teixeira AR 2000. Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi ni-troderivatives. Am J Trop Med Hyg 63: 111-118.
24. Lauria-Pires L, de Castro CN, Emanuel A, Prata A 1988. Ineffectiveness of allopurinol in patients in the acute phase of Chagas disease. Rev Soc Bras Med Trop 21: 79.
25. Macedo VO, Silveira CA 1987. Perspectivas da terapêutica específica na doença de Chagas. Experiências na forma indeterminada. Rev Soc Bras Med Trop 20 (Suppl. II): M24-M26.
26. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV 2007. Pathogenesis of chronic Chagas heart disease. Circulation 115: 1109-1123.
27. Marin-Neto JA, Marzullo P, Marcassa C, Gallo Jr L, Maciel BC, Bellina CR, L'Abbate AL 1992. Myocardial perfusion abnormalities in chronic Chagas' disease as detected by thallium-201 scintigraphy. Am J Cardiol 69: 780-784.
28. Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas F, Yusuf S 2008. BENEFIT investigators. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156: 37-43.
29. Miranda L, Miranda L, Campos G, Marins N, Lobo V 1994. História natural da forma crônica da doença de Chagas x tratamento espe-cífico. RECOC 1: 25-29.
30. Prata A 2001. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92-100.
31. Rassi A, Luquetti AO, Rassi A Jr, Rassi GG, Rassi SG, DA Silva IG, Rassi AG 2007. Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am J Trop Med Hyg 76: 58-61.
32. Rassi A, Rassi Jr. A, Rassi GG 2000. Fase aguda. In: Z Brener, ZA Andrade, M Barral-Neto (eds.), Trypanosoma cruzi e doença de Chagas, Guanabara Koogan, Rio de Janeiro, p. 231-245.
33. Rassi Jr A, Rassi A, Little WC 2006. Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 355: 799-808.
34. Reyes PA, Vallejo M 2005. Trypanocidal drugs for late stage, symptomatic CD (Trypanosoma cruzi infection). Cochrane Database Syst Rev: CD004102.
35. Rossi MA 1990. Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease. Am Heart J 120: 233-236.
36. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yam-potis C 1998. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am J Trop Med Hyg 59: 526-529.
37. Tarleton RL 2003. Trypanosoma cruzi and Chagas disease: cause and effect. In: KM Tyler, MA Miles (eds.), World class parasites: American trypanosomiasis, Vol. 7, Kluwer Academic Publisher, Norwell, p. 107-116.
38. Villar JC 2002. Desenlaces clínicos de sujetos com infección crônica por Trypanosoma cruzi tratados o no con agentes tripanocidas. Un metaanálisis de estúdios observacionales. MEDUNAB 5: 166-173.
39. Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S 2002. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev: CD003463.
40. Viotti R, Vigliano C, Armenti H, Segura E 1994. Treatment of chronic Chagas disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 127: 151-162.
41. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, Postan M, Armenti A 2006. Long-term cardiac outcomes of treating chronic CD with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724-734.